DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
Open Access
- 16 August 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 10, 724
Abstract
Immune checkpoint inhibitor (ICI) treatment could bring long-lasting clinical benefits to patients with metastatic cancer. However, only a small proportion of patients respond to PD-1/PD-L1 blockade, so predictive biomarkers are needed. Here, based on DNA methylation profiles and the objective response rates (ORRs) of PD-1/PD-L1 inhibition therapy, we identified 269 CpG sites and developed an initial CpG-based model by Lasso to predict ORRs. Notably, as measured by the area under the receiver operating characteristic curve (AUC), our model can produce better performance (AUC = 0.92) than both a model based on tumor mutational burden (TMB) (AUC = 0.77) and a previously reported TMB model (AUC = 0.71). In addition, most CpGs also have additional synergies with TMB, which can achieve a higher prediction accuracy when joined with TMB. Furthermore, we identified CpGs that are associated with TMB at the individual level. DNA methylation modules defined by protein networks, Kyoto Encylopedia of Genes and Genomes (KEGG) pathways, and ligand-receptor gene pairs are also associated with ORRs. This method suggested novel immuno-oncology targets that might be beneficial when combined with PD-1/PD-L1 blockade. Thus, DNA methylation studies might hold great potential for individualized PD1/PD-L1 blockade or combinatory therapy.Keywords
Funding Information
- National Natural Science Foundation of China (91129708)
- State Key Laboratory of Space Medicine Fundamentals and Application, China Astronaut Research and Training Center (SMFA09A07, SMFA10A03, SMFA13A04)
This publication has 64 references indexed in Scilit:
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- STRING v9.1: protein-protein interaction networks, with increased coverage and integrationNucleic Acids Research, 2012
- MR1 presents microbial vitamin B metabolites to MAIT cellsNature, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Cancer epigenetics reaches mainstream oncologyNature Medicine, 2011
- Cancer epigenetics: linking basic biology to clinical medicineCell Research, 2011
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Perceptions of epigeneticsNature, 2007
- Improvements on Cross-Validation: The 632+ Bootstrap MethodJournal of the American Statistical Association, 1997